Immedica publishes Business Review and Annual & Sustainability Report 2025

Immedica publishes Business Review and Annual & Sustainability Report 2025 Thu, Apr 30, 2026 14:00 CET Report this content Stockholm, Sweden, April 30, 2026 – Immedica today today announces the publication of its Business Review and Annual & Sustainability Report 2025. During 2025, Immedica delivered strong strategic progress marked by portfolio expansion, geographic growth and continued investment in sustainable long-term value creation. The year was characterised by decisive execution, growing global reach and a reinforced focus on improving patient access to treatments in rare diseases worldwide. Key highlights from 2025 Clear strategic momentum and expansion Immedica strengthened its position as a global rare disease company through the acquisition of Marinus Pharmaceuticals, establishing a presence in the United States and expanding into RARE Neurology . Toward year-end, Immedica also signed a definitive agreement to acquire Neurocrine Group Ltd, adding RARE Endocrinology as a new therapeutic area. Broadened portfolio addressing high unmet medical needs Immedica’s portfolio expanded across RARE Metabolic, RARE Neurology, RARE Hematology & Oncology and Specialty Care. During the year, regulatory progress enabled broader patient access in multiple geographies, with key approvals and submissions advancing across Europe, MENA and LATAM. Strong financial performance Proforma net sales for 2025 amounted to EUR 134.5 million , reflecting robust underlying growth across therapeutic areas. Immedica’s financial position and cash generation support continued strategic investments in portfolio development and geographic expansion. People, culture and sustainability at the core Immedica was certified as a Great Place To Work® for the third consecutive year, achieving a global Trust Index score of 93% . Sustainability remains integrated into Immedica’s business model, with continued progress across environmental, social and governance priorities aligned with the UN Sustainable Development Goals. CEO statement “2025 was a year of growth, momentum and strong execution. With an expanded global footprint, a growing portfolio and a dedicated organization, Immedica has never been better positioned to deliver lasting impact for patients with rare diseases, healthcare systems and society at large.” — Anders Edvell , Chief Executive Officer The full Business Review and Annual & Sustainability Report 2025 is available at www.immedica.com . About Immedica Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica’s therapeutic areas are within RARE Metabolic, RARE Hematology & Oncology, RARE Neurology, RARE Endocrinology and specialty care. Immedica was founded in 2018 and employs today around 180 people across Europe, the Middle East and the United States. Immedica is backed by the investment firms KKR and Impilo. For more information visit www.immedica.com . Immedica contact: Linda Holmström Head of HR & Communication linda.holmstrom@immedica.com Formulärets överkant Formulärets nederkant Immedica Pharma AB Solnavägen 3H SE-113 63 Stockholm